logo
Twitter
Discord
Email
logo
Boston Scientific Corporation

Boston Scientific Corporation

NYSE•BSX
CEO: Mr. Michael F. Mahoney
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-05-19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Contact Information
300 Boston Scientific Way, Marlborough, MA, 01752-1234, United States
508-683-4000
www.bostonscientific.com
Market Cap
$148.62B
P/E (TTM)
53.3
vs Industry 37.6
Dividend Yield (TTM)
--
52W High
$109.50
52W Low
$80.64
52W Range
68%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$5.07B+0.00%
4-Quarter Trend

EPS

$0.51+0.00%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

McKesson CorporationMCK
$377.60B
+20.3%
Pfizer Inc.PFE
$63.83B
+13.5%
SanofiSNY
$46.90B
+9.3%

Gross Margin (Latest Quarter)

Gilead Sciences, Inc.GILD
78.8%
+1.0 pp
SanofiSNY
72.1%
-19.0 pp
Boston Scientific CorporationBSX
67.7%
+4.9 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ABT$216.57B15.529.9%16.0%
ISRG$192.04B69.815.6%0.0%
AMGN$157.08B23.797.9%63.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+3.6%
Moderate Growth
4-Quarter Net Income CAGR
+10.1%
Gradual Improvement in Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 1, 2025|
    Revenue: $5.06B+22.8%
    |
    EPS: $0.54+145.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $4.66B+20.9%
    |
    EPS: $0.46+35.4%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 18, 2025|
    Revenue: $16.75B+17.6%
    |
    EPS: $1.26+16.6%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 1, 2024|
    Revenue: $4.21B+19.3%
    |
    EPS: $0.32-7.6%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $4.12B+14.5%
    |
    EPS: $0.22+22.1%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $3.86B+13.8%
    |
    EPS: $0.34+61.4%
    Miss
  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $14.24B+12.3%
    |
    EPS: $1.08+140.8%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 20, 2024|Refer to amended data